FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382362641> ?p ?o ?g. }

• W4382362641 abstract "Abstract Background Ovarian cancer is a gynecological malignancy with a high incidence and mortality. Optimal tumor reduction surgery is crucial for improving the prognosis of advanced ovarian cancer patients. Traditional platinum-based neoadjuvant chemotherapy (NACT) can increase the chances of surgical treatment for advanced ovarian cancer and reduce the difficulty of surgery. However, NACT has limited benefits for patients. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) combined with antiangiogenic treatment increase the clinical benefits to ovarian cancer patients. Therefore, we hypothesize that PARPis combined with antiangiogenic neoadjuvant therapy (NAT) can improve the R0 resection rate of advanced ovarian cancer while avoiding platinum resistance caused by NACT. Methods This study is a prospective, interventional, single-arm, open-label, phase II clinical trial. Patients with stage III or IV advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer (collectively referred to as ovarian cancer per the International Federation of Gynecology and Obstetrics (FIGO) staging 2018) who are unable to achieve R0 tumor reduction surgery after imaging or laparoscopic evaluation or cannot tolerate surgery will be recruited. The patient will receive NAT with three cycles of pamiparib combined with surufatinib (pamiparib: 40 mg, twice daily, 3 weeks per cycle, treatment for three cycles; surufatinib: 250 mg, once daily, 3 weeks per cycle, treatment for two cycles), followed by surgery. The main endpoint will be the assessment of the R0 resection rate. The secondary study endpoints will be the objective response rate (ORR), pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and adverse events (AEs). Discussion This is the first prospective study to evaluate the efficacy and safety of PARPis combined with antiangiogenic therapy for newly diagnosed advanced ovarian cancer. Drug combinations are a key component in experimental design. We hope that this promising treatment strategy can provide new options for patients with advanced ovarian cancer. Trial registration ClinicalTrials.gov, NCT05652283. Registered on 27 November 2022." @default.
• W4382362641 created "2023-06-29" @default.
• W4382362641 creator A5010721975 @default.
• W4382362641 creator A5012355541 @default.
• W4382362641 creator A5022701602 @default.
• W4382362641 creator A5035181295 @default.
• W4382362641 creator A5038738121 @default.
• W4382362641 creator A5046378338 @default.
• W4382362641 creator A5049660752 @default.
• W4382362641 creator A5060604602 @default.
• W4382362641 creator A5061192928 @default.
• W4382362641 creator A5061970522 @default.
• W4382362641 creator A5062157219 @default.
• W4382362641 creator A5065515283 @default.
• W4382362641 creator A5082020327 @default.
• W4382362641 creator A5082692509 @default.
• W4382362641 creator A5084470003 @default.
• W4382362641 creator A5089619775 @default.
• W4382362641 creator A5091833934 @default.
• W4382362641 creator A5092348912 @default.
• W4382362641 date "2023-06-28" @default.
• W4382362641 modified "2023-09-23" @default.
• W4382362641 title "Pamiparib Combined with Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer: A Single-Arm, Prospective, Single-Center Clinical Study Protocol" @default.
• W4382362641 cites W1539571840 @default.
• W4382362641 cites W1569243391 @default.
• W4382362641 cites W1968704850 @default.
• W4382362641 cites W2023322537 @default.
• W4382362641 cites W2076743146 @default.
• W4382362641 cites W2095467773 @default.
• W4382362641 cites W2156500939 @default.
• W4382362641 cites W2200242714 @default.
• W4382362641 cites W2274165065 @default.
• W4382362641 cites W2913578326 @default.
• W4382362641 cites W2920708123 @default.
• W4382362641 cites W2970135300 @default.
• W4382362641 cites W2994977341 @default.
• W4382362641 cites W3020297583 @default.
• W4382362641 cites W3022572023 @default.
• W4382362641 cites W3026903046 @default.
• W4382362641 cites W3041730055 @default.
• W4382362641 cites W3092412842 @default.
• W4382362641 cites W3186488429 @default.
• W4382362641 cites W3193045657 @default.
• W4382362641 cites W3201437718 @default.
• W4382362641 cites W3211666548 @default.
• W4382362641 cites W3214182319 @default.
• W4382362641 cites W4226026458 @default.
• W4382362641 cites W4294982904 @default.
• W4382362641 doi "https://doi.org/10.21203/rs.3.rs-3036908/v1" @default.
• W4382362641 hasPublicationYear "2023" @default.
• W4382362641 type Work @default.
• W4382362641 citedByCount "0" @default.
• W4382362641 crossrefType "posted-content" @default.
• W4382362641 hasAuthorship W4382362641A5010721975 @default.
• W4382362641 hasAuthorship W4382362641A5012355541 @default.
• W4382362641 hasAuthorship W4382362641A5022701602 @default.
• W4382362641 hasAuthorship W4382362641A5035181295 @default.
• W4382362641 hasAuthorship W4382362641A5038738121 @default.
• W4382362641 hasAuthorship W4382362641A5046378338 @default.
• W4382362641 hasAuthorship W4382362641A5049660752 @default.
• W4382362641 hasAuthorship W4382362641A5060604602 @default.
• W4382362641 hasAuthorship W4382362641A5061192928 @default.
• W4382362641 hasAuthorship W4382362641A5061970522 @default.
• W4382362641 hasAuthorship W4382362641A5062157219 @default.
• W4382362641 hasAuthorship W4382362641A5065515283 @default.
• W4382362641 hasAuthorship W4382362641A5082020327 @default.
• W4382362641 hasAuthorship W4382362641A5082692509 @default.
• W4382362641 hasAuthorship W4382362641A5084470003 @default.
• W4382362641 hasAuthorship W4382362641A5089619775 @default.
• W4382362641 hasAuthorship W4382362641A5091833934 @default.
• W4382362641 hasAuthorship W4382362641A5092348912 @default.
• W4382362641 hasBestOaLocation W43823626411 @default.
• W4382362641 hasConcept C121608353 @default.
• W4382362641 hasConcept C126322002 @default.
• W4382362641 hasConcept C141071460 @default.
• W4382362641 hasConcept C143998085 @default.
• W4382362641 hasConcept C203092338 @default.
• W4382362641 hasConcept C2780427987 @default.
• W4382362641 hasConcept C535046627 @default.
• W4382362641 hasConcept C71924100 @default.
• W4382362641 hasConceptScore W4382362641C121608353 @default.
• W4382362641 hasConceptScore W4382362641C126322002 @default.
• W4382362641 hasConceptScore W4382362641C141071460 @default.
• W4382362641 hasConceptScore W4382362641C143998085 @default.
• W4382362641 hasConceptScore W4382362641C203092338 @default.
• W4382362641 hasConceptScore W4382362641C2780427987 @default.
• W4382362641 hasConceptScore W4382362641C535046627 @default.
• W4382362641 hasConceptScore W4382362641C71924100 @default.
• W4382362641 hasLocation W43823626411 @default.
• W4382362641 hasOpenAccess W4382362641 @default.
• W4382362641 hasPrimaryLocation W43823626411 @default.
• W4382362641 hasRelatedWork W1608269846 @default.
• W4382362641 hasRelatedWork W182989684 @default.
• W4382362641 hasRelatedWork W2002120878 @default.
• W4382362641 hasRelatedWork W2047967234 @default.
• W4382362641 hasRelatedWork W2439875401 @default.
• W4382362641 hasRelatedWork W2789668336 @default.
• W4382362641 hasRelatedWork W3089163820 @default.
• W4382362641 hasRelatedWork W3204289211 @default.
• W4382362641 hasRelatedWork W4282918911 @default.

• next